BIIB Forecast



Bearish<—>Bullish



80% Confidence




Bullish Case: Biogen's strategic partnership in RNAi therapies, leverage of breakthrough Alzheimer's treatments, and undervaluation relative to historical prices present potential upside.




Bearish Case: Ongoing regulatory scrutiny, significant market competition, and recent price decline suggest potential risks to Biogen's stock performance.




Potential Outcomes:
  • Significant new drug approval: 45%
  • Further regulatory challenges: 30%
  • Strategic M&A boosts: 25%



June 20, 2025


Biogen Forecast

BIIB        Biogen











Correlated Assets

Assets that tend to move strongly with BIIB



NVO Forecast + Options Trading Strategies   NVO  Novo Nordisk (0.97)


KSS Forecast + Options Trading Strategies   KSS  Kohl's (0.97)


MUR Forecast + Options Trading Strategies   MUR  Murphy Oil (0.96)


REGN Forecast + Options Trading Strategies   REGN  Regeneron Pharmaceuticals (0.95)


DOW Forecast + Options Trading Strategies   DOW  Dow (0.95)



Uncorrelated Assets

Assets with little price relationship to BIIB



EA Forecast + Options Trading Strategies   EA  Electronic Arts (0.01)


FITB Forecast + Options Trading Strategies   FITB  Fifth Third Bancorp (-0.01)


XLK Forecast + Options Trading Strategies   XLK  Technology Select Sector SPDR (0.01)


KKR Forecast + Options Trading Strategies   KKR  KKR (-0.02)


DNA Forecast + Options Trading Strategies   DNA  Ginkgo Bioworks (-0.02)



Anticorrelated Assets

Assets that tend to move strongly against BIIB



VRSN Forecast + Options Trading Strategies   VRSN  Verisign (-0.91)


ATO Forecast + Options Trading Strategies   ATO  Atmos Energy (-0.91)


SAP Forecast + Options Trading Strategies   SAP  Sap SE (-0.92)


CORT Forecast + Options Trading Strategies   CORT  Corcept Therapeutics (-0.94)


LRN Forecast + Options Trading Strategies   LRN  Stride (-0.94)









Become a more profitable investor with AI optimized trading strategies






×

Chat with BIIB


 Ask any question about BIIB!